PTPN11 and neoplasm: One possible therapy for such combinations might be inhibitors of SHP2: these not only suppress the adaptive rewiring of signalling within the cancer cells that diminishes sensitivity to KRASG12C inhibition, but can also directly affect signalling of non-cancer cells within the TME and enhance anti-tumour immune responses15,30–33.